Biocon Full Year 2025 Earnings: Beats Expectations

Biocon (NSE:BIOCON) Full Year 2025 Results

Key Financial Results

• Revenue: ₹152.6b (up 3.4% from FY 2024).
• Net income: ₹10.1b (flat on FY 2024).
• Profit margin: 6.6% (down from 6.9% in FY 2024).
• EPS: ₹8.46 (down from ₹8.55 in FY 2024).

This technology could replace computers: discover the 20 stocks are working to make quantum computing a reality.

All figures shown in the chart above are for the trailing 12 month (TTM) period

Biocon Revenues and Earnings Beat Expectations

Revenue exceeded analyst estimates by 1.8%. Earnings per share (EPS) also surpassed analyst estimates by 16%.

The primary driver behind last 12 months revenue was the Biosimilars segment contributing a total revenue of ₹90.2b (59% of total revenue). The largest operating expense was General & Administrative costs, amounting to ₹31.7b (38% of total expenses). Explore how BIOCON's revenue and expenses shape its earnings.

Looking ahead, revenue is forecast to grow 14% p.a. on average during the next 3 years, compared to a 23% growth forecast for the Biotechs industry in Asia.

Performance of the market in India.

The company's shares are down 1.1% from a week ago.

Risk Analysis

Don't forget that there may still be risks. For instance, we've identified 2 warning signs for Biocon (1 is potentially serious) you should be aware of.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.